文献速递核素与放射性配体治疗

225Ac-DOTATATE治疗高SSTR表达神经内分泌肿瘤的疗效与安全性

Efficacy and Safety of 225 Ac-DOTATATE in the Treatment of Neuroendocrine Neoplasms With High SSTR Expression.
PubMed 文献 · Clin Nucl Med · 2024-03-18

这项单中心前瞻性研究纳入10例经组织学诊断且68Ga-DOTATATE PET/CT显示SSTR表达增高的神经内分泌肿瘤(NEN)患者,评估225Ac-DOTATATE靶向α治疗的疗效与安全性。分子影像部分缓解40%、疾病稳定40%、疾病进展20%,疾病控制率80%;既往接受177Lu-DOTATATE治疗者疾病控制率为83.3%(5/6)。未观察到III/IV级血液学、肾脏及肝脏毒性,中位随访14个月(7-22个月),无死亡报告。

要点

  • 分子影像疾病控制率为80%,部分缓解40%、疾病稳定40%、疾病进展20%
  • 既往177Lu-DOTATATE治疗者疾病控制率为83.3%(5/6)
  • 未观察到III/IV级血液学、肾脏及肝脏毒性,无死亡报告

核心结论

  • 这项初步研究提示,225Ac-DOTATATE可能是治疗SSTR表达增高的NEN的一种有前景的选择,毒性谱可接受且不良反应耐受良好。

研究设计与样本

  • 单中心前瞻性研究,纳入10例经组织学诊断且68Ga-DOTATATE PET/CT显示SSTR表达增高的NEN患者,所有患者均接受225Ac-DOTATATE靶向α治疗。

主要发现

  • 分子影像部分缓解见于40%的患者,疾病稳定40%,疾病进展20%,疾病控制率80%。
  • 既往接受177Lu-DOTATATE治疗的患者疾病控制率为83.3%(5/6)。
  • 根据EORTC QLQ-C30 v3.0评分,225Ac-DOTATATE治疗后多数症状改善,仅腹泻无改善。
  • 未观察到III/IV级血液学、肾脏及肝脏毒性;中位随访14个月(7-22个月),无死亡报告。

关键数值与推荐

  • 主要终点为基于分子影像的缓解和疾病控制率,采用稍作修改的实体瘤PET缓解标准1.0评估。
  • 不良事件谱依据不良事件通用术语标准5.0版判定。
  • 临床缓解采用EORTC QLQ-C30 v3.0(欧洲癌症研究与治疗组织核心生活质量问卷3.0版)评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to evaluate the efficacy and safety of 225 Ac-DOTATATE targeted α therapy (TAT) in various neuroendocrine neoplasms (NENs) with high somatostatin receptor (SSTR) expression. PATIENTS AND METHODS: This single-center prospective study included 10 patients with histologically diagnosed NENs that exhibited increased SSTR expression on 68 Ga-DOTATATE PET/CT imaging. All patients received 225 Ac-DOTATATE TAT. The primary end points were molecular imaging-based response and disease control rate (DCR), measured using the slightly modified Positron Emission Tomography Response Criteria in Solid Tumors 1.0. The secondary end points were adverse event profiles and clinical responses. The adverse event profile was determined according to the Common Terminology Criteria for Adverse Events version 5.0. Clinical response was assessed using the EORTC QLQ-C30 v3.0 (European Organization for Research and Treatment of Cancer Core Quality of Life questionnaire version 3.0). RESULTS: A molecular imaging-based partial response was observed in 40% of all patients, SD in 40%, PD in 20%, and DCR in 80%. The DCR was 83.3% (5/6) in patients who were previously treated with 177 Lu-DOTATATE. According to the EORTC QLQ-C30 v3.0 score, most symptoms improved after 225 Ac-DOTATATE treatment, with only diarrhea showing no improvement. Grade III/IV hematological, kidney, and liver toxicities were not observed. The median follow-up time was 14 months (7-22 months), and no deaths were reported. CONCLUSIONS: This initial study suggests that 225 Ac-DOTATATE is a potentially promising option for treating NENs with elevated SSTR expression, with an acceptable toxicity profile and well-tolerated adverse effects.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Yang H, Zhang Y, Li H, et al. Efficacy and Safety of 225 Ac-DOTATATE in the Treatment of Neuroendocrine Neoplasms With High SSTR Expression. Clin Nucl Med. 2024. PMID: 38498615. doi:10.1097/RLU.0000000000005149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。